bupropion has been researched along with Drug Withdrawal Symptoms in 115 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the relative efficacy of varenicline and bupropion SR plus intensive counseling on smoking cessation and emotional functioning." | 9.17 | Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. ( Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW, 2013) |
| "Psychoactive effects of smoking cessation medi cations such as bupropion may allow participants in smoking cessation clinical trials to correctly guess their treatment assignment at rates greater than chance." | 9.17 | Perceived treatment assignment and smoking cessation in a clinical trial of bupropion versus placebo. ( Ahluwalia, JS; Berg, CJ; Buchanan, TS; Mayo, MS; Nollen, NL; Sanderson Cox, L; Thomas, JL, 2013) |
| "This proof-of-concept study investigated the feasibility and initial efficacy of combining a contingency management intervention with bupropion to reduce smoking in people with schizophrenia." | 9.15 | Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. ( Kaplan, GB; Reid, N; Rohsenow, DJ; Swift, RM; Tidey, JW, 2011) |
| "A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain." | 9.14 | An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010) |
| "This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms." | 9.14 | A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010) |
| " Neither bupropion SR nor smoking abstinence significantly altered the positive or negative symptoms of schizophrenia." | 9.13 | A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. ( Allen, TM; Creeden, CL; Dudas, MM; Feingold, A; George, TP; Jatlow, PI; Potenza, MN; Sacco, KA; Vessicchio, JC; Weinberger, AH, 2008) |
| "Treatment with CBT + bupropion resulted in a better 6-month rate of smoking cessation compared to CBT+nortriptyline or CBT + placebo." | 9.12 | A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. ( Cesari, DH; Chatkin, JM; Fam, CF; Fritscher, CC; Haggsträm, FM; Sussenbach-Vaz, E, 2006) |
| "This 6-week, randomized, open-label pilot study estimated the treatment effect size of gabapentin (n = 17) compared with bupropion SR (n = 19) for smoking cessation, thereby allowing sample size calculations for a definitive comparison study." | 9.11 | A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. ( Crockford, D; El-Guebaly, N; Patten, S; White, WD, 2005) |
| "The objective of this study was to examine the effects of tobacco abstinence and bupropion treatment on cognitive functioning in adult smokers with schizophrenia in the setting of a randomized, double-blind, placebo-controlled clinical trial of bupropion for smoking cessation." | 9.11 | Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. ( Cather, C; Culhane, MA; Deckersbach, T; Evins, AE; Freudenreich, O; Goff, DC; Green, MF; Henderson, DC; Rigotti, NA; Schoenfeld, DA, 2005) |
| "Bupropion sustained release (bupropion SR) has been shown to increase smoking cessation success rates in the US studies." | 9.10 | A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. ( Hider, A; Hjalmarson, A; Lebargy, F; Sweet, R; Tonstad, S; Townsend, J; Tønnesen, P; Van Spiegel, PI, 2003) |
| "Treatment with sustained-release bupropion alone or in combination with a nicotine patch resulted in significantly higher long-term rates of smoking cessation than use of either the nicotine patch alone or placebo." | 9.09 | A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. ( Baker, TB; Daughton, DM; Doan, K; Fiore, MC; Hughes, AR; Johnston, JA; Jorenby, DE; Leischow, SJ; Muramoto, ML; Nides, MA; Rennard, SI; Smith, SS, 1999) |
| "A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects." | 9.08 | A comparison of sustained-release bupropion and placebo for smoking cessation. ( Croghan, IT; Dale, LC; Glover, ED; Glover, PN; Hurt, RD; Johnston, JA; Khayrallah, MA; Offord, KP; Sachs, DP; Schroeder, DR; Sullivan, CR; Sullivan, PM, 1997) |
| "To review the efficacy of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation." | 8.93 | Nicotine receptor partial agonists for smoking cessation. ( Cahill, K; Fanshawe, TR; Lancaster, T; Lindson-Hawley, N; Thomas, KH, 2016) |
| " Fifteen trials compared varenicline with placebo for smoking cessation; three of these also included a bupropion treatment arm." | 8.88 | Nicotine receptor partial agonists for smoking cessation. ( Cahill, K; Lancaster, T; Stead, LF, 2012) |
| "We found 11 trials of varenicline compared with placebo for smoking cessation; three of these included a bupropion experimental arm." | 8.87 | Nicotine receptor partial agonists for smoking cessation. ( Cahill, K; Lancaster, T; Stead, LF, 2011) |
| "We found 11 trials of varenicline compared with placebo for smoking cessation; three of these included a bupropion experimental arm." | 8.86 | Nicotine receptor partial agonists for smoking cessation. ( Cahill, K; Lancaster, T; Stead, LF, 2010) |
| "Varenicline is a recently developed medication for smoking cessation, which has been available on prescription since 2006." | 8.85 | A preliminary benefit-risk assessment of varenicline in smoking cessation. ( Cahill, K; Lancaster, T; Stead, L, 2009) |
| "Bupropion exhibits reasonable efficacy as a smoking cessation aid, yet its precise mechanisms of action remain unclear." | 8.82 | How does bupropion work as a smoking cessation aid? ( Shoaib, M; Warner, C, 2005) |
| " Sustained-release bupropion (bupropion SR) is the first non-nicotine pharmacological treatment approved for smoking cessation." | 8.81 | Clinical efficacy of bupropion in the management of smoking cessation. ( Jorenby, D, 2002) |
| "Bupropion and varenicline are non-nicotine medications used for smoking cessation that mitigate craving and withdrawal symptoms." | 7.88 | Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study. ( Galanti, MR; Hansson, J; Janszky, I; Möller, J; Monárrez-Espino, J; Söderberg-Löfdal, K, 2018) |
| " The aim of this study was to evaluate the effectiveness of varenicline in monotherapy or in combined therapy with bupropion and/or serotonin reuptake inhibitors (SRIs) in a specific cardiovascular smoking cessation service." | 7.79 | Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. ( Abe, TO; Issa, JS; Moura, S; Pereira, AC; Santos, PC, 2013) |
| "In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents." | 7.74 | Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. ( Shoaib, M; Wing, VC, 2007) |
| "Bupropion was associated with slower lapse during treatment for both sexes, and being female was associated with faster lapse across both phases." | 6.71 | Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. ( Audrain-McGovern, J; Brown, RA; Epstein, LH; Hawk, LW; Lerman, C; Niaura, R; Patterson, F; Wileyto, EP, 2005) |
| "Bupropion was devoid of intrinsic analgesic activity and did not enhance morphine acute analgesia." | 5.48 | Bupropion attenuates morphine tolerance and dependence: Possible role of glutamate, norepinephrine, inflammation, and oxidative stress. ( Barakat, A; Elbadr, MM; Hamdy, MM, 2018) |
| "Acute dystonia is commonly associated with high-potency antipsychotics." | 5.34 | Acute dystonia resulting from abrupt bupropion discontinuation. ( Chou, WJ; Huang, TY; Hung, CF; Wang, HY, 2007) |
| " In conclusion, chronic administration of bupropion (2 and 5 mg/kg) exhibited a significant protection against triazolam withdrawal-induced anxiety and hyperlocomotor activity in mice." | 5.33 | Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice. ( Joshi, D; Kulkarni, SK; Naidu, PS; Singh, A, 2005) |
| "As part of a randomized controlled trial of smoking cessation therapies, 1122 adults (58% female) were assigned to: placebo (n = 131), bupropion (alone or with nicotine lozenge; n = 401), or nicotine replacement therapy (NRT; lozenge, patch, both; n = 590)." | 5.24 | Anhedonia: Its Dynamic Relations With Craving, Negative Affect, and Treatment During a Quit Smoking Attempt. ( Baker, TB; Chu, W; Cook, JW; Lanza, ST; Piper, ME, 2017) |
| "Bupropion is used to treat depression during pregnancy." | 5.24 | Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. ( Ahmed, MS; Clark, SM; Feinn, RS; Fokina, VM; Hankins, GDV; Jain, SK; Nanovskaya, TN; Oncken, C; West, H, 2017) |
| "Participants were weight-concerned women (n = 349) ages 18-65 enrolled in a randomized, double-blind, placebo-controlled smoking cessation trial of bupropion and cognitive behavioral therapy." | 5.20 | A test of the stress-buffering model of social support in smoking cessation: is the relationship between social support and time to relapse mediated by reduced withdrawal symptoms? ( Cheng, Y; Creswell, KG; Levine, MD, 2015) |
| "To assess the relative efficacy of varenicline and bupropion SR plus intensive counseling on smoking cessation and emotional functioning." | 5.17 | Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. ( Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW, 2013) |
| "Psychoactive effects of smoking cessation medi cations such as bupropion may allow participants in smoking cessation clinical trials to correctly guess their treatment assignment at rates greater than chance." | 5.17 | Perceived treatment assignment and smoking cessation in a clinical trial of bupropion versus placebo. ( Ahluwalia, JS; Berg, CJ; Buchanan, TS; Mayo, MS; Nollen, NL; Sanderson Cox, L; Thomas, JL, 2013) |
| " The purpose of this study was to determine the effect of bupropion (an agent known to increase smoking cessation rates) on the craving, withdrawal, and mood response to stressful tasks administered in a laboratory setting." | 5.15 | Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers. ( Adson, DE; al'Absi, M; Brauer, L; Drone, D; Hatsukami, DK; Kotlyar, M; Thuras, P, 2011) |
| " Smokers with anxiety disorders reported higher levels of nicotine dependence and pre-quit withdrawal symptoms." | 5.15 | Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. ( Baker, TB; Cook, JW; Jorenby, DE; Piper, ME; Schlam, TR, 2011) |
| "This proof-of-concept study investigated the feasibility and initial efficacy of combining a contingency management intervention with bupropion to reduce smoking in people with schizophrenia." | 5.15 | Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. ( Kaplan, GB; Reid, N; Rohsenow, DJ; Swift, RM; Tidey, JW, 2011) |
| "This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms." | 5.14 | A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010) |
| "A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain." | 5.14 | An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010) |
| " Neither bupropion SR nor smoking abstinence significantly altered the positive or negative symptoms of schizophrenia." | 5.13 | A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. ( Allen, TM; Creeden, CL; Dudas, MM; Feingold, A; George, TP; Jatlow, PI; Potenza, MN; Sacco, KA; Vessicchio, JC; Weinberger, AH, 2008) |
| "Treatment with CBT + bupropion resulted in a better 6-month rate of smoking cessation compared to CBT+nortriptyline or CBT + placebo." | 5.12 | A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. ( Cesari, DH; Chatkin, JM; Fam, CF; Fritscher, CC; Haggsträm, FM; Sussenbach-Vaz, E, 2006) |
| "This 6-week, randomized, open-label pilot study estimated the treatment effect size of gabapentin (n = 17) compared with bupropion SR (n = 19) for smoking cessation, thereby allowing sample size calculations for a definitive comparison study." | 5.11 | A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. ( Crockford, D; El-Guebaly, N; Patten, S; White, WD, 2005) |
| "The objective of this study was to examine the effects of tobacco abstinence and bupropion treatment on cognitive functioning in adult smokers with schizophrenia in the setting of a randomized, double-blind, placebo-controlled clinical trial of bupropion for smoking cessation." | 5.11 | Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. ( Cather, C; Culhane, MA; Deckersbach, T; Evins, AE; Freudenreich, O; Goff, DC; Green, MF; Henderson, DC; Rigotti, NA; Schoenfeld, DA, 2005) |
| "Bupropion sustained release (bupropion SR) has been shown to increase smoking cessation success rates in the US studies." | 5.10 | A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. ( Hider, A; Hjalmarson, A; Lebargy, F; Sweet, R; Tonstad, S; Townsend, J; Tønnesen, P; Van Spiegel, PI, 2003) |
| "Treatment with sustained-release bupropion alone or in combination with a nicotine patch resulted in significantly higher long-term rates of smoking cessation than use of either the nicotine patch alone or placebo." | 5.09 | A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. ( Baker, TB; Daughton, DM; Doan, K; Fiore, MC; Hughes, AR; Johnston, JA; Jorenby, DE; Leischow, SJ; Muramoto, ML; Nides, MA; Rennard, SI; Smith, SS, 1999) |
| "Bupropion has demonstrated efficacy for smoking cessation." | 5.09 | The effect of bupropion on nicotine craving and withdrawal. ( DeVeaugh-Geiss, J; Elash, CA; Evoniuk, G; Gnys, M; Gwaltney, CJ; Johnston, JA; Khayrallah, M; Paty, JA; Shiffman, S, 2000) |
| "Bupropion is used clinically as a treatment for smoking cessation, but the processes by which it reduces smoking are poorly understood." | 5.09 | Acute doses of d-amphetamine and bupropion increase cigarette smoking. ( Cousins, MS; de Wit, H; Stamat, HM, 2001) |
| "A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects." | 5.08 | A comparison of sustained-release bupropion and placebo for smoking cessation. ( Croghan, IT; Dale, LC; Glover, ED; Glover, PN; Hurt, RD; Johnston, JA; Khayrallah, MA; Offord, KP; Sachs, DP; Schroeder, DR; Sullivan, CR; Sullivan, PM, 1997) |
| "To review the efficacy of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation." | 4.93 | Nicotine receptor partial agonists for smoking cessation. ( Cahill, K; Fanshawe, TR; Lancaster, T; Lindson-Hawley, N; Thomas, KH, 2016) |
| " In the United States there are medications available to treat tobacco use disorders (nicotine replacement, bupropion, and varenicline), alcohol use disorders (naltrexone and acamprosate), and opioid use disorders (methadone and buprenorphine)." | 4.93 | Pharmacotherapy for Substance Use Disorders. ( Klein, JW, 2016) |
| " In this commentary, we briefly summarize the extant literature on pharmacotherapies in opioid-maintained smokers and contribute new data investigating the contribution of bupropion on smoking outcomes in 81 methadone- and buprenorphine-maintained participants from two randomized trials of financial incentives for smoking cessation." | 4.91 | Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions. ( Miller, ME; Sigmon, SC, 2015) |
| " Despite concerns regarding adolescent nicotine dependence, few well-designed smoking cessation studies have been conducted with teen smokers." | 4.88 | Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. ( Ammerman, S; Bailey, SR; Crew, EE; Killen, JD; Riske, EC; Robinson, TN, 2012) |
| " Fifteen trials compared varenicline with placebo for smoking cessation; three of these also included a bupropion treatment arm." | 4.88 | Nicotine receptor partial agonists for smoking cessation. ( Cahill, K; Lancaster, T; Stead, LF, 2012) |
| "We found 11 trials of varenicline compared with placebo for smoking cessation; three of these included a bupropion experimental arm." | 4.87 | Nicotine receptor partial agonists for smoking cessation. ( Cahill, K; Lancaster, T; Stead, LF, 2011) |
| "Randomised controlled trials and meta-analyses have demonstrated that single therapy with either NRT, bupropion or varenicline are all more effective than placebo for smoking cessation." | 4.86 | Smoking cessation-recent advances. ( Ioannides-Demos, LL; McNeil, JJ; Piccenna, L, 2010) |
| "We found 11 trials of varenicline compared with placebo for smoking cessation; three of these included a bupropion experimental arm." | 4.86 | Nicotine receptor partial agonists for smoking cessation. ( Cahill, K; Lancaster, T; Stead, LF, 2010) |
| "Varenicline is a recently developed medication for smoking cessation, which has been available on prescription since 2006." | 4.85 | A preliminary benefit-risk assessment of varenicline in smoking cessation. ( Cahill, K; Lancaster, T; Stead, L, 2009) |
| "Varenicline significantly reduces craving and the rewarding effects of smoking after the TQD to a greater extent than bupropion, which may contribute to varenicline's greater efficacy for smoking cessation." | 4.84 | Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. ( Baker, CL; Bushmakin, AG; Cappelleri, JC; West, R, 2008) |
| "Over the past decade, bupropion has become a major pharmacotherapy for smoking cessation in the Western world." | 4.83 | Bupropion for the treatment of nicotine withdrawal and craving. ( Mooney, ME; Sofuoglu, M, 2006) |
| " The limitation of these approaches is shown by their insensitivity to effects of nicotine replacement and bupropion, which are effective in clinical trials for smoking cessation." | 4.83 | Medication screening for smoking cessation: a proposal for new methodologies. ( Lerman, C; Perkins, KA; Stitzer, M, 2006) |
| "Bupropion exhibits reasonable efficacy as a smoking cessation aid, yet its precise mechanisms of action remain unclear." | 4.82 | How does bupropion work as a smoking cessation aid? ( Shoaib, M; Warner, C, 2005) |
| "This review summarises the evidence on how bupropion sustained release (SR) works, its contraindications and risks, adverse effects, studies on efficacy and place in smoking cessation pharmacotherapy." | 4.81 | Bupropion sustained release. A therapeutic review of Zyban. ( Richmond, R; Zwar, N, 2002) |
| " Sustained-release bupropion (bupropion SR) is the first non-nicotine pharmacological treatment approved for smoking cessation." | 4.81 | Clinical efficacy of bupropion in the management of smoking cessation. ( Jorenby, D, 2002) |
| " Effective approaches to smoking cessation include behavioural intervention and pharmacotherapy, in particular nicotine replacement therapy (NRT) and sustained-release bupropion (bupropion SR)." | 4.81 | Current approaches to the management of smoking cessation. ( Sutherland, G, 2002) |
| "Bupropion and varenicline are non-nicotine medications used for smoking cessation that mitigate craving and withdrawal symptoms." | 3.88 | Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study. ( Galanti, MR; Hansson, J; Janszky, I; Möller, J; Monárrez-Espino, J; Söderberg-Löfdal, K, 2018) |
| "In this global health case study, we describe a case of nicotine addiction due to chronic use of electronic cigarettes (e-cigarette) and discuss the beliefs on safety and awareness of their side effects." | 3.88 | Beliefs and reality of e-cigarette smoking. ( Inzamam Ali, M; Menakuru, S, 2018) |
| "Intensive longitudinal data from a randomized placebo-controlled smoking cessation trial (N=1504) are used to estimate a dynamical model of withdrawal-related processes including momentary craving, negative affect, quitting self-efficacy, and cessation fatigue for each of six treatment conditions (nicotine patch, nicotine lozenge, bupropion, patch + lozenge, bupropion + lozenge, and placebo)." | 3.85 | Evaluating the effect of smoking cessation treatment on a complex dynamical system. ( Bekiroglu, K; Lagoa, CM; Lanza, ST; Piper, ME; Russell, MA, 2017) |
| " The aim of this study was to evaluate the effectiveness of varenicline in monotherapy or in combined therapy with bupropion and/or serotonin reuptake inhibitors (SRIs) in a specific cardiovascular smoking cessation service." | 3.79 | Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. ( Abe, TO; Issa, JS; Moura, S; Pereira, AC; Santos, PC, 2013) |
| "The objective of this study was to estimate the continuous abstinence rates of varenicline, bupropion and nicotine replacement therapy (NRT) in smoking cessation in 2 Primary Care (PC) External Support Units." | 3.77 | [Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care]. ( Díaz Cerezo, S; Martí Sánchez, B; Navarro Artieda, R; Sanz De Burgoa, V; Sicras Mainar, A, 2011) |
| "Bupropion, a norepinephrine and dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, facilitates smoking cessation and reduces some symptoms of nicotine withdrawal." | 3.74 | Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. ( Gould, TJ; Portugal, GS, 2007) |
| "In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents." | 3.74 | Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. ( Shoaib, M; Wing, VC, 2007) |
| "Chronic nicotine infusion reduces the synthesis of 5HTT protein, which may consequently precipitate depression during nicotine withdrawal, but co-administration of bupropion may ameliorate withdrawal symptoms by counteracting nicotine's effect on 5HTT." | 3.74 | Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion. ( Semba, J; Wakuta, M, 2008) |
| " A case is reported of a patient treated with bupropion as a smoking cessation medication, who developed somnambulism during nicotine withdrawal." | 3.72 | Bupropion-induced somnambulism. ( Khazaal, Y; Krenz, S; Zullino, DF, 2003) |
| "Few studies have examined whether nicotine dependence self-report questionnaires can predict specific behaviors and symptoms at specific points in time." | 2.74 | Do smokers know what we're talking about? The construct validity of nicotine dependence questionnaire measures. ( Baker, TB; Bolt, DM; Japuntich, SJ; Piper, ME; Schlam, TR, 2009) |
| "Measures of desire to smoke and of five withdrawal symptoms were taken before taking the tablets, and then at 5 min intervals for 20 min." | 2.71 | Effect of glucose on tobacco withdrawal symptoms in recent quitters using bupropion or nicotine replacement. ( Hajek, P; McRobbie, H, 2004) |
| "Bupropion is a weak dopamine reuptake inhibitor, and individual genetic variation in the dopamine D2 receptor has been associated with nicotine dependence in case-control studies." | 2.71 | Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? ( Britt, DM; Burkholder, GJ; David, SP; Day, A; Griffiths, SE; Hutchison, K; Johnstone, E; Murphy, M; Niaura, R; Papandonatos, GD; Shadel, WG; Stumpff, J; Walton, RT, 2003) |
| "Bupropion was associated with slower lapse during treatment for both sexes, and being female was associated with faster lapse across both phases." | 2.71 | Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. ( Audrain-McGovern, J; Brown, RA; Epstein, LH; Hawk, LW; Lerman, C; Niaura, R; Patterson, F; Wileyto, EP, 2005) |
| "SR bupropion was titrated over the first three out-patient days followed by a fixed dose (300 mg/day) for 14 days (including the three in-patient abstinence days)." | 2.71 | Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. ( Bye, A; Milleri, S; Squassante, L; Teneggi, V; Tiffany, ST; Ziviani, L, 2005) |
| "Smoking cessation was measured after at least six months, using the most rigorous definition available, on an intention-to-treat basis." | 2.61 | Smoking reduction interventions for smoking cessation. ( Aveyard, P; Hong, B; Klemperer, E; Lindson, N; Ordóñez-Mena, JM, 2019) |
| " Self-reported withdrawal symptoms for 7 days after the planned quit date, and 7-day point prevalence and continuous abstinence at EOT and 6 months." | 2.48 | Comparative dynamics of four smoking withdrawal symptom scales. ( Javitz, HS; Lerman, C; Swan, GE, 2012) |
| "Patients with COPD show higher nicotine dependence and seem to have greater difficulty in quitting smoking." | 2.47 | [Smoking in COPD]. ( Bernabé Barrios, MJ; Rodríguez Hermosa, JL; Santamaría Rodríguez, B; Zamarro García, C, 2011) |
| "Smoking cessation is an important factor in the primary and secondary prevention of cardiac events." | 2.43 | Smoking cessation in patients with coronary artery disease. ( Eisenberg, MJ; Ludvig, J; Miner, B, 2005) |
| " Several studies have reported on long-term use of various pharmacotherapies." | 2.41 | Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy? ( Fiore, MC; Sims, TH, 2002) |
| "Varenicline treatment duration is a significant predictive factor for successful smoking abstinence (odds ratio (OR) = 2." | 1.72 | Abstinence Rate, Adverse Events and Withdrawal Symptoms after Varenicline Use and Predicting Factors of Smoking Abstinence: A Multicentre Single-State Study in Malaysia. ( Chang, CT; Choo, SJ; Harun, SN; Latif, MFA; Sanusi, NA; Tangiisuran, B, 2022) |
| "Craving and other withdrawal symptoms were minimal, and CC smoking satisfaction declined markedly, while satisfaction ratings for ENDS increased over time to overtake those of CC." | 1.72 | Bupropion/zonisamide combination to assist smokers to switch from combustible cigarettes to electronic nicotine delivery systems (ENDS). ( Behm, FM; Botts, DR; Botts, TL; Rose, JE; Willette, PN, 2022) |
| "Bupropion was devoid of intrinsic analgesic activity and did not enhance morphine acute analgesia." | 1.48 | Bupropion attenuates morphine tolerance and dependence: Possible role of glutamate, norepinephrine, inflammation, and oxidative stress. ( Barakat, A; Elbadr, MM; Hamdy, MM, 2018) |
| "Elderly, well-educated employees with breathlessness on exertion have higher odds of quitting smoking." | 1.40 | Predictors of success for smoking cessation at the workplace: a longitudinal study. ( Fagerström, KO; Kuster, M; Meyer, A; Scherr, A; Seiffert, B; Stolz, D; Tamm, M, 2014) |
| "Bupropion is an atypical antidepressant that also has utility as a smoking cessation aid." | 1.36 | Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. ( Blough, BE; Carroll, FI; Damaj, MI; Grabus, SD; King, LS; Lukas, RJ; Navarro, HA; Vann, RE; Warner, JA; Wiley, JL, 2010) |
| "Bupropion is an effective anti-smoking agent in humans, but the behavioral mechanisms mediating this effect are unclear." | 1.35 | Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats. ( Balfour, DJ; Markou, A; Paterson, NE, 2008) |
| "Acute dystonia is commonly associated with high-potency antipsychotics." | 1.34 | Acute dystonia resulting from abrupt bupropion discontinuation. ( Chou, WJ; Huang, TY; Hung, CF; Wang, HY, 2007) |
| " In conclusion, chronic administration of bupropion (2 and 5 mg/kg) exhibited a significant protection against triazolam withdrawal-induced anxiety and hyperlocomotor activity in mice." | 1.33 | Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice. ( Joshi, D; Kulkarni, SK; Naidu, PS; Singh, A, 2005) |
| "Bipolar affective disorders can be successfully treated with long-term use of the mood stabilizer lithium." | 1.33 | Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat. ( Ferrie, L; McQuade, R; Young, AH, 2005) |
| "Constipation is mentioned occasionally as a possible tobacco withdrawal symptom, but no systematic data have been published on this issue." | 1.32 | Stopping smoking can cause constipation. ( Gillison, F; Hajek, P; McRobbie, H, 2003) |
| "Bupropion is an atypical antidepressant and the only non-nicotine-based therapy approved for smoking cessation." | 1.32 | Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. ( Bruijnzeel, AW; Cryan, JF; Markou, A; Skjei, KL, 2003) |
| "After taking bupropion, his withdrawal symptoms i." | 1.31 | Bupropion for amphetamine withdrawal syndrome. ( Boonyanaruthee, V; Chan-Ob, T; Kuntawongse, N, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (6.09) | 18.2507 |
| 2000's | 57 (49.57) | 29.6817 |
| 2010's | 48 (41.74) | 24.3611 |
| 2020's | 3 (2.61) | 2.80 |
| Authors | Studies |
|---|---|
| Ciccarone, D | 1 |
| Shoptaw, S | 2 |
| Rose, JE | 1 |
| Willette, PN | 1 |
| Botts, TL | 1 |
| Botts, DR | 1 |
| Behm, FM | 1 |
| Choo, SJ | 1 |
| Chang, CT | 1 |
| Tangiisuran, B | 1 |
| Latif, MFA | 1 |
| Sanusi, NA | 1 |
| Harun, SN | 1 |
| Lindson, N | 1 |
| Klemperer, E | 1 |
| Hong, B | 1 |
| Ordóñez-Mena, JM | 1 |
| Aveyard, P | 1 |
| Dailey, JI | 1 |
| Wilson, KC | 1 |
| Cook, JW | 3 |
| Lanza, ST | 2 |
| Chu, W | 1 |
| Baker, TB | 9 |
| Piper, ME | 6 |
| Monárrez-Espino, J | 1 |
| Galanti, MR | 1 |
| Hansson, J | 1 |
| Janszky, I | 1 |
| Söderberg-Löfdal, K | 1 |
| Möller, J | 1 |
| Bekiroglu, K | 1 |
| Russell, MA | 1 |
| Lagoa, CM | 1 |
| De la Torre-Colmenero, JD | 1 |
| Arjona-Padillo, A | 1 |
| Fernandez-Perez, J | 1 |
| Hamdy, MM | 1 |
| Elbadr, MM | 1 |
| Barakat, A | 1 |
| Menakuru, S | 1 |
| Inzamam Ali, M | 1 |
| Hugley, MJ | 1 |
| Wolford-Clevenger, C | 1 |
| Sisson, ML | 1 |
| Nguyen, AT | 1 |
| Cropsey, KL | 1 |
| Gilbert, DG | 1 |
| Rabinovich, NE | 1 |
| Gilbert-Matuskowitz, EA | 1 |
| Klein, KP | 1 |
| Pergadia, ML | 1 |
| Ahmadi, J | 1 |
| Sahraian, A | 1 |
| Biuseh, M | 1 |
| Cinciripini, PM | 2 |
| Robinson, JD | 2 |
| Karam-Hage, M | 2 |
| Minnix, JA | 2 |
| Lam, C | 1 |
| Versace, F | 2 |
| Brown, VL | 2 |
| Engelmann, JM | 2 |
| Wetter, DW | 2 |
| Stolz, D | 1 |
| Scherr, A | 1 |
| Seiffert, B | 1 |
| Kuster, M | 1 |
| Meyer, A | 1 |
| Fagerström, KO | 1 |
| Tamm, M | 1 |
| Perkins, KA | 3 |
| Karelitz, JL | 2 |
| Jao, NC | 2 |
| Gur, RC | 1 |
| Lerman, C | 6 |
| Hays, JT | 2 |
| Giasson-Gariépy, K | 1 |
| Jutras-Aswad, D | 1 |
| Jiménez-Ruiz, CA | 1 |
| Pascual Lledó, JF | 1 |
| Cicero Guerrero, A | 1 |
| Mayayo Ulibarri, M | 1 |
| Cristóbal Fernández, M | 1 |
| Perera López, L | 1 |
| Creswell, KG | 1 |
| Cheng, Y | 1 |
| Levine, MD | 1 |
| Miller, ME | 1 |
| Sigmon, SC | 1 |
| Cahill, K | 5 |
| Lindson-Hawley, N | 1 |
| Thomas, KH | 1 |
| Fanshawe, TR | 1 |
| Lancaster, T | 5 |
| Mooney, ME | 2 |
| Schmitz, JM | 1 |
| Allen, S | 1 |
| Grabowski, J | 1 |
| Pentel, P | 1 |
| Oliver, A | 1 |
| Hatsukami, DK | 3 |
| Klein, JW | 1 |
| Nanovskaya, TN | 1 |
| Oncken, C | 1 |
| Fokina, VM | 1 |
| Feinn, RS | 1 |
| Clark, SM | 1 |
| West, H | 1 |
| Jain, SK | 1 |
| Ahmed, MS | 1 |
| Hankins, GDV | 1 |
| Paterson, NE | 2 |
| Balfour, DJ | 2 |
| Markou, A | 3 |
| Semba, J | 1 |
| Wakuta, M | 1 |
| McCarthy, DE | 1 |
| Piasecki, TM | 3 |
| Lawrence, DL | 1 |
| Jorenby, DE | 6 |
| Shiffman, S | 4 |
| Croghan, IT | 2 |
| Ebbert, JO | 2 |
| Hurt, RD | 2 |
| Dale, LC | 2 |
| Warner, N | 1 |
| Schroeder, DR | 3 |
| Killen, JD | 2 |
| Fortmann, SP | 1 |
| Schatzberg, AF | 1 |
| Arredondo, C | 1 |
| Murphy, G | 1 |
| Hayward, C | 1 |
| Celio, M | 1 |
| Cromp, D | 1 |
| Fong, D | 1 |
| Pandurangi, M | 1 |
| Dent, LA | 1 |
| Harris, KJ | 1 |
| Noonan, CW | 1 |
| Stead, L | 1 |
| Henningfield, JE | 1 |
| Ferguson, SG | 1 |
| Gritz, ER | 1 |
| Nanchen, D | 1 |
| Willi, C | 1 |
| Peytremann-Bridevaux, I | 1 |
| Burnand, B | 1 |
| Walther, MR | 1 |
| Wilcox, CS | 1 |
| Oskooilar, N | 1 |
| Erickson, JS | 1 |
| Billes, SK | 1 |
| Katz, BB | 1 |
| Tollefson, G | 1 |
| Dunayevich, E | 1 |
| Japuntich, SJ | 1 |
| Schlam, TR | 3 |
| Bolt, DM | 3 |
| Schnoll, RA | 1 |
| Martinez, E | 1 |
| Tatum, KL | 1 |
| Weber, DM | 1 |
| Kuzla, N | 1 |
| Glass, M | 1 |
| Ridge, JA | 1 |
| Langer, C | 1 |
| Miyamoto, C | 1 |
| Wileyto, EP | 3 |
| Leone, F | 1 |
| Kravos, M | 1 |
| Damaj, MI | 1 |
| Grabus, SD | 1 |
| Navarro, HA | 1 |
| Vann, RE | 1 |
| Warner, JA | 1 |
| King, LS | 1 |
| Wiley, JL | 1 |
| Blough, BE | 1 |
| Lukas, RJ | 1 |
| Carroll, FI | 1 |
| McNeil, JJ | 1 |
| Piccenna, L | 1 |
| Ioannides-Demos, LL | 1 |
| Gonzales, D | 1 |
| Brandon, TH | 1 |
| Arteaga, C | 1 |
| Lee, TC | 1 |
| Stead, LF | 3 |
| Kotlyar, M | 2 |
| Drone, D | 1 |
| Thuras, P | 2 |
| Brauer, L | 1 |
| Adson, DE | 2 |
| al'Absi, M | 2 |
| Sicras Mainar, A | 1 |
| Navarro Artieda, R | 1 |
| Díaz Cerezo, S | 1 |
| Martí Sánchez, B | 1 |
| Sanz De Burgoa, V | 1 |
| Sheffer, MA | 1 |
| Smith, SS | 4 |
| Loh, WY | 1 |
| Kim, SY | 1 |
| Kaye, JT | 1 |
| Hefner, KR | 1 |
| Tidey, JW | 1 |
| Rohsenow, DJ | 1 |
| Kaplan, GB | 1 |
| Swift, RM | 1 |
| Reid, N | 1 |
| Simon, JA | 1 |
| Javitz, HS | 2 |
| Swan, GE | 2 |
| Theobald, WE | 1 |
| Bailey, SR | 1 |
| Crew, EE | 1 |
| Riske, EC | 1 |
| Ammerman, S | 1 |
| Robinson, TN | 1 |
| Severson, HH | 1 |
| Danaher, BG | 1 |
| Glover, ED | 2 |
| Buchanan, TS | 1 |
| Sanderson Cox, L | 1 |
| Thomas, JL | 1 |
| Nollen, NL | 1 |
| Berg, CJ | 1 |
| Mayo, MS | 1 |
| Ahluwalia, JS | 1 |
| Cui, Y | 1 |
| Lam, CY | 1 |
| Dani, JA | 1 |
| Kosten, TR | 1 |
| Stratton, E | 1 |
| Issa, JS | 1 |
| Abe, TO | 1 |
| Moura, S | 1 |
| Santos, PC | 1 |
| Pereira, AC | 1 |
| Zamarro García, C | 1 |
| Bernabé Barrios, MJ | 1 |
| Santamaría Rodríguez, B | 1 |
| Rodríguez Hermosa, JL | 1 |
| Jorenby, D | 1 |
| Sutherland, G | 1 |
| Sims, TH | 1 |
| Fiore, MC | 4 |
| Haney, M | 2 |
| Cryan, JF | 1 |
| Bruijnzeel, AW | 1 |
| Skjei, KL | 1 |
| Tønnesen, P | 1 |
| Tonstad, S | 2 |
| Hjalmarson, A | 1 |
| Lebargy, F | 1 |
| Van Spiegel, PI | 1 |
| Hider, A | 1 |
| Sweet, R | 1 |
| Townsend, J | 1 |
| Khazaal, Y | 1 |
| Krenz, S | 1 |
| Zullino, DF | 1 |
| Hajek, P | 2 |
| Gillison, F | 1 |
| McRobbie, H | 2 |
| David, SP | 1 |
| Niaura, R | 3 |
| Papandonatos, GD | 1 |
| Shadel, WG | 1 |
| Burkholder, GJ | 1 |
| Britt, DM | 1 |
| Day, A | 1 |
| Stumpff, J | 1 |
| Hutchison, K | 1 |
| Murphy, M | 1 |
| Johnstone, E | 1 |
| Griffiths, SE | 1 |
| Walton, RT | 1 |
| Michael, N | 1 |
| Erfurth, A | 1 |
| Bergant, V | 1 |
| Johnston, JA | 4 |
| Taraschenko, OD | 1 |
| Panchal, V | 1 |
| Maisonneuve, IM | 1 |
| Glick, SD | 1 |
| Ferrie, L | 1 |
| Young, AH | 1 |
| McQuade, R | 1 |
| Ludvig, J | 1 |
| Miner, B | 1 |
| Eisenberg, MJ | 1 |
| Patterson, F | 2 |
| Epstein, LH | 2 |
| Brown, RA | 1 |
| Audrain-McGovern, J | 1 |
| Hawk, LW | 1 |
| Joshi, D | 1 |
| Naidu, PS | 1 |
| Singh, A | 1 |
| Kulkarni, SK | 1 |
| Warner, C | 1 |
| Shoaib, M | 2 |
| Jepson, C | 1 |
| Rukstalis, M | 1 |
| Kaufmann, V | 1 |
| Restine, S | 1 |
| Hawk, L | 1 |
| Berrettini, W | 1 |
| Teneggi, V | 1 |
| Tiffany, ST | 1 |
| Squassante, L | 1 |
| Milleri, S | 1 |
| Ziviani, L | 1 |
| Bye, A | 1 |
| Malin, DH | 1 |
| Lake, JR | 1 |
| Smith, TD | 1 |
| Khambati, HN | 1 |
| Meyers-Paal, RL | 1 |
| Montellano, AL | 1 |
| Jennings, RE | 1 |
| Erwin, DS | 1 |
| Presley, SE | 1 |
| Perales, BA | 1 |
| Stitzer, M | 1 |
| Evins, AE | 1 |
| Deckersbach, T | 1 |
| Cather, C | 1 |
| Freudenreich, O | 1 |
| Culhane, MA | 1 |
| Henderson, DC | 1 |
| Green, MF | 1 |
| Schoenfeld, DA | 1 |
| Rigotti, NA | 1 |
| Goff, DC | 1 |
| White, WD | 1 |
| Crockford, D | 1 |
| Patten, S | 1 |
| El-Guebaly, N | 1 |
| Haggsträm, FM | 1 |
| Chatkin, JM | 1 |
| Sussenbach-Vaz, E | 1 |
| Cesari, DH | 1 |
| Fam, CF | 1 |
| Fritscher, CC | 1 |
| Brauer, LH | 1 |
| Robiner, W | 1 |
| Harris, J | 1 |
| Finocchi, ME | 1 |
| Bronars, CA | 1 |
| Candell, S | 1 |
| Sofuoglu, M | 1 |
| Ling, W | 2 |
| Rawson, R | 1 |
| Wang, HY | 1 |
| Chou, WJ | 1 |
| Huang, TY | 1 |
| Hung, CF | 1 |
| Toll, BA | 1 |
| Schepis, TS | 1 |
| O'Malley, SS | 1 |
| McKee, SA | 1 |
| Krishnan-Sarin, S | 1 |
| Frishman, WH | 1 |
| Wing, VC | 1 |
| Portugal, GS | 1 |
| Gould, TJ | 1 |
| West, R | 1 |
| Baker, CL | 1 |
| Cappelleri, JC | 1 |
| Bushmakin, AG | 1 |
| George, TP | 1 |
| Vessicchio, JC | 1 |
| Sacco, KA | 1 |
| Weinberger, AH | 1 |
| Dudas, MM | 1 |
| Allen, TM | 1 |
| Creeden, CL | 1 |
| Potenza, MN | 1 |
| Feingold, A | 1 |
| Jatlow, PI | 1 |
| Kampman, KM | 1 |
| Nunes, EV | 1 |
| McGrath, PJ | 1 |
| Quitkin, FM | 1 |
| Sachs, DP | 1 |
| Offord, KP | 1 |
| Khayrallah, MA | 1 |
| Glover, PN | 1 |
| Sullivan, CR | 1 |
| Sullivan, PM | 1 |
| Benowitz, NL | 1 |
| Farnam, CR | 1 |
| Leischow, SJ | 1 |
| Nides, MA | 1 |
| Rennard, SI | 1 |
| Hughes, AR | 1 |
| Muramoto, ML | 1 |
| Daughton, DM | 1 |
| Doan, K | 1 |
| Jiménez Ruiz, CA | 1 |
| Khayrallah, M | 1 |
| Elash, CA | 1 |
| Gwaltney, CJ | 1 |
| Paty, JA | 1 |
| Gnys, M | 1 |
| Evoniuk, G | 1 |
| DeVeaugh-Geiss, J | 1 |
| Ward, AS | 1 |
| Comer, SD | 1 |
| Hart, CL | 1 |
| Foltin, RW | 1 |
| Fischman, MW | 1 |
| Cousins, MS | 1 |
| Stamat, HM | 1 |
| de Wit, H | 1 |
| Chan-Ob, T | 1 |
| Kuntawongse, N | 1 |
| Boonyanaruthee, V | 1 |
| Zwar, N | 1 |
| Richmond, R | 1 |
| Taeron, C | 1 |
| Yutrzenka, GJ | 1 |
| Patrick, GA | 1 |
| Rosenberger, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NRT & Bupropion Mechanisms of Effectiveness in Smokers: Phase IV Trial[NCT01048944] | Phase 4 | 197 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Pharmacogenetics, Emotional Reactivity and Smoking[NCT00507728] | Phase 2/Phase 3 | 646 participants (Actual) | Interventional | 2005-12-08 | Completed | ||
| The Acute Effects of Moderate Intensity Exercise and Nicotine on Cognition in Smokers[NCT03091699] | Phase 3 | 34 participants (Anticipated) | Interventional | 2017-05-01 | Recruiting | ||
| Nicotine Replacement Therapy After Acute Coronary Syndrome[NCT03209622] | 89 participants (Actual) | Interventional | 2015-01-02 | Completed | |||
| Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation[NCT00419731] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2006-11-30 | Recruiting | ||
| Bupropion for Smoking Cessation During Pregnancy[NCT01390246] | Phase 4 | 65 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Project 3: Identifying Optimal Strategies of Increasing Smokers' Adherence to Cessation Medications[NCT01120704] | Phase 4 | 544 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Behavioral Maintenance Treatment for Smoking Cessation[NCT00110825] | 304 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Behavioral Maintenance Treatment for Smoking Cessation[NCT01615770] | 304 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Efficacy and Cost-Effectiveness of an Intensive and Abbreviated Individualized Smoking Cessation Support Program Delivered by Pharmacists: A Randomized Controlled Trial[NCT03597607] | 150 participants (Actual) | Interventional | 2018-09-18 | Completed | |||
| A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation[NCT00143364] | Phase 3 | 1,005 participants | Interventional | 2003-06-30 | Completed | ||
| A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation[NCT00141206] | Phase 3 | 1,005 participants | Interventional | 2003-05-31 | Completed | ||
| Incentives Plus Bupropion for Smoking in Schizophrenics[NCT00136760] | Phase 2 | 57 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Bio-behavioral Lung Cancer Prevention Program[NCT00322205] | Phase 4 | 555 participants | Interventional | 1999-06-30 | Completed | ||
| Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy - Transdisciplinary Tobacco Use Research Center (TTURC), Project 2[NCT00326781] | Phase 4 | 674 participants (Actual) | Interventional | 1999-12-31 | Completed | ||
| Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence[NCT00749658] | Phase 2/Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| An Innovative Digital Smoking Cessation Intervention for Low-Income Adults With Substance Use Disorder[NCT04419922] | 100 participants (Actual) | Observational | 2020-04-02 | Active, not recruiting | |||
| Does an Acute Bout of Exercise Affect Smoking Satisfaction?[NCT01417975] | 43 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Optimizing Treatment for Schizophrenic Smokers[NCT00124683] | Phase 2 | 59 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation[NCT00633321] | Phase 2 | 522 participants (Anticipated) | Interventional | 2007-05-31 | Completed | ||
| The STOP Study: Real World Effectiveness of Zyban Treatment in a Clinical Population[NCT01015170] | Phase 4 | 454 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Brain-wave activity (EEG) was assessed using electrodes on the subject's scalp, the outputs of which were and quantified by a commercial brain wave machine. EEG was collected at frontal (e.g., Fz) and parietal (e.g., Pz) electrodes while subjects relaxed. EEG was analyzed using computer programs that measured slow-frequency EEG waves known as delta (1.5-4.5 cycles/second [cps]), theta-1 (4.5-6.0 cps), theta-2 (6.0-7.7 cps), and alpha-1 (7.8-10.0 cps), and higher frequency waves. Generally, delta, alpha-1 and theta waves reflect deactivation of the brain activity, while higher frequency waves reflect greater brain activation. Brain activity was quantified as the natural log of EEG power [microvolts squared] as determined by the fast Fourier mathematical algorithm. Days post quit were components of Time. The primary focus was on changes in the individual subject's log theta-1, theta-2, and alpha-1 power at post-quit points in time minus the log values at the pre-quite baseline. (NCT01048944)
Timeframe: Mean EEG power [microvolts squared] from at baseline, 3, 24, 45, and 66 days post-quit
| Intervention | Change in log EEG [microvolts squared] (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day-3 Change in log Theta-1 EEG Power Fz | Day-24 Change in log Theta-1 EEG Power Fz | Day-45 Change in log Theta-1 Power Fz | Day-66 Change in log Theta-1 EEG Power Fz | Day-3 Change in log Theta-2 Power Fz | Day-24 Change in log Theta-2 Power Fz | Day-45 Change in log Theta-2 Power Fz | Day-66 Change in log Theta-2 Power Fz | Day-3 Change in log Alpha-1 Power Pz | Day-24 Change in log Alpha-1 Power Pz | Day 45 Change in log Alpha-1 Power Pz | Day 66 Change in log Alpha-1 Power Pz | |
| Bupropion SR | .224 | .198 | .249 | .407 | .088 | .150 | .248 | .502 | .155 | .301 | .261 | .459 |
| Delayed-quit Control | -.094 | -.060 | -.032 | -.026 | -.070 | -.042 | .054 | .001 | -.004 | -.001 | .021 | .017 |
| Nicotine Patch | .055 | .194 | .232 | .431 | .062 | .251 | .319 | .504 | -.023 | .139 | .292 | .339 |
| Placebo Patch and Placebo Pill | .234 | .258 | .161 | .184 | .249 | .278 | .278 | .205 | .184 | .276 | .259 | .292 |
"Changes in log from baseline in the widely used Shiffman-Jarvik Withdrawal craving and psychological symptom scores through 66 days of abstinence. Post-quit changes were assessed at days 3, 24, 45, and 66 of abstinence. The maximal range of value raw for craving is from 5 = (no craving) to 47 (maximally strong craving), while that for psychological symptoms is from 5 (no symptoms) to 60 (maximally intense symptoms of across multiple symptoms). Because the subtraction of logs is equivalent to the ratio of the two scores, a difference in logs (base 10) with a value of 1 is equal to an increase by a factor of 10, while a value of 0 is no change, and values of less than 0 are decreases below baseline values." (NCT01048944)
Timeframe: Changes in log withdrawal symptoms from baseline through 66 days of abstinence
| Intervention | log (base 10) units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day-3 Change in log Shiffman Craving | Day-24 Change in log Shiffman Craving | Day-45 Change in log Shiffman Craving | Day-66 Change in log Shiffman Craving | Day-3 Change in log Shiffman Psych Withdrawal | Day-24 Change in log Shiffman Psych W | Day-45 Change in log Shiffman Psych Withdrawal | Day-66 Change in log Shiffman Psych Withdrawal | |
| Bupropion SR | .045 | -.199 | -.201 | -.230 | .210 | .102 | .063 | .032 |
| Delayed-quit Control | -.045 | -.059 | -.043 | -.075 | .016 | -.025 | -.017 | -.012 |
| Nicotine Patch | -.006 | -.187 | -.273 | -.236 | .089 | .065 | .008 | .068 |
| Placebo Patch and Placebo Pill | .094 | -.045 | -.132 | -.205 | .172 | .076 | .039 | .029 |
Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Varenicline w/o DRD2 A1 Allele | 8.084 |
| Varenicline With DRD2 A1 Allele | 6.847 |
| Bupropion w/o DRD2 A1 Allele | 7.588 |
| Bupropion With DRD2 A1 Allele | 8.362 |
| Placebo w/o DRD2 A1 Allele | 8.65 |
| Placebo With DRD2 A1 Allele | 10.799 |
Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 6 Month ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)
| Intervention | probability (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 0.001 | 0.001 | 0 | 0.001 |
| Bupropion With DRD2 A1 Allele | -0.001 | -0.002 | -0.001 | -0.001 |
| Placebo w/o DRD2 A1 Allele | 0 | 0 | 0 | 0 |
| Placebo With DRD2 A1 Allele | -0.005 | -0.004 | -0.004 | -0.004 |
| Varenicline w/o DRD2 A1 Allele | 0.003 | 0.003 | 0.003 | 0.003 |
| Varenicline With DRD2 A1 Allele | -0.001 | -0.001 | 0 | -0.001 |
Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval. (NCT00507728)
Timeframe: Baseline to 1 month
| Intervention | microvolts (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion | 64.7 | 73.1 | 65.4 | 64.9 |
| Placebo | 65.6 | 65.6 | 64.7 | 72.5 |
| Varenicline | 66.6 | 70.9 | 66.7 | 59.6 |
The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype. (NCT00507728)
Timeframe: Baseline to 1 month
| Intervention | microvolts (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 66.2 | 78.6 | 71.3 | 73.9 |
| Bupropion With DRD2 A1 Allele | 66 | 71.3 | 63.3 | 61.2 |
| Placebo w/o DRD2 A1 Allele | 67.3 | 74 | 68.5 | 79.7 |
| Placebo With DRD2 A1 Allele | 68.1 | 68.1 | 63.8 | 67.8 |
| Varenicline w/o DRD2 A1 Allele | 66.5 | 70.5 | 65.5 | 55.3 |
| Varenicline With DRD2 A1 Allele | 69.9 | 75.1 | 72 | 67.2 |
Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype. (NCT00507728)
Timeframe: Baseline to 1 month
| Intervention | beats per minute (Least Squares Mean) | |||
|---|---|---|---|---|
| Heart Rate response to Cigarette Stimuli | Heart Rate response to Negative Stimuli | Heart Rate response to Positive Stimuli | Heart Rate response to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 71.427 | 71.077 | 71.518 | 71.706 |
| Bupropion With DRD2 A1 Allele | 69.836 | 69.595 | 70.404 | 70.234 |
| Placebo w/o DRD2 A1 Allele | 65.966 | 65.768 | 65.787 | 65.237 |
| Placebo With DRD2 A1 Allele | 65.276 | 65.569 | 65.927 | 66.04 |
| Varenicline w/o DRD2 A1 Allele | 69.731 | 69.562 | 69.151 | 69.621 |
| Varenicline With DRD2 A1 Allele | 68.652 | 68.078 | 68.711 | 68.969 |
Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items. (NCT00507728)
Timeframe: Baseline to 8 months
| Intervention | score on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Smoking Satisfaction | Psychological Reward | Aversion | Enjoyment of Respiratory Tract Sensation | Craving Reduction | |
| Bupropion w/o DRD2 A1 Allele | 4.064 | 2.519 | 1.988 | 4.096 | 4.564 |
| Bupropion With DRD2 A1 Allele | 3.369 | 2.723 | 1.79 | 1.955 | 6.628 |
| Placebo w/o DRD2 A1 Allele | 3.025 | 3.575 | 1.808 | 3.711 | 4.486 |
| Placebo With DRD2 A1 Allele | 3.515 | 3.246 | 1.69 | 2.783 | 4.673 |
| Varenicline w/o DRD2 A1 Allele | 2.895 | 2.819 | 1.612 | 1.912 | 4.531 |
| Varenicline With DRD2 A1 Allele | 2.591 | 2.155 | 1.694 | 1.703 | 3.952 |
Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval. (NCT00507728)
Timeframe: Baseline to 1 month
| Intervention | Microsiemens (Least Squares Mean) | |||
|---|---|---|---|---|
| Skin conductance to Cigarette Stimuli | Skin conductance to Negative Stimuli | Skin conductance to Positive Stimuli | Skin conductance to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 2.275 | 2.31 | 2.299 | 2.369 |
| Bupropion With DRD2 A1 Allele | 1.797 | 1.695 | 1.7 | 1.699 |
| Placebo w/o DRD2 A1 Allele | 2.272 | 2.355 | 2.296 | 2.362 |
| Placebo With DRD2 A1 Allele | 2.443 | 2.485 | 2.565 | 2.559 |
| Varenicline w/o DRD2 A1 Allele | 2.301 | 2.295 | 2.256 | 2.261 |
| Varenicline With DRD2 A1 Allele | 2.016 | 1.969 | 1.984 | 2.017 |
Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 3 months
| Intervention | probability (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion | -0.01 | -0.009 | -0.01 | -0.008 |
| Placebo | -0.008 | -0.007 | -0.007 | -0.007 |
| Varenicline | -0.003 | -0.004 | -0.003 | -0.004 |
Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 3 Month
| Intervention | probability (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigarette Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion w/o DRD2 A1 Allele | 0 | 0 | 0 | 0.001 |
| Bupropion With DRD2 A1 Allele | -0.003 | -0.004 | -0.003 | -0.002 |
| Placebo w/o DRD2 A1 Allele | -0.001 | -0.001 | -0.001 | -0.001 |
| Placebo With DRD2 A1 Allele | -0.004 | -0.004 | -0.004 | -0.003 |
| Varenicline w/o DRD2 A1 Allele | 0.001 | 0.002 | 0.001 | 0.001 |
| Varenicline With DRD2 A1 Allele | -0.004 | -0.005 | -0.005 | -0.005 |
Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Abstinence at 6 Months ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)
| Intervention | probability (Least Squares Mean) | |||
|---|---|---|---|---|
| Emotional Reactivity (ORB) to Cigaretee Stimuli | Emotional Reactivity (ORB) to Negative Stimuli | Emotional Reactivity (ORB) to Positive Stimuli | Emotional Reactivity (ORB) to Neutral Stimuli | |
| Bupropion | -0.002 | -0.003 | -0.003 | -0.001 |
| Placebo | -0.006 | -0.005 | -0.005 | -0.005 |
| Varenicline | 0.007 | 0.008 | 0.01 | 0.008 |
Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months
| Intervention | score on a scale (Least Squares Mean) | |
|---|---|---|
| Positive Affect | Negative Affect | |
| Bupropion w/o DRD2 A1 Allele | 36.429 | 15.782 |
| Bupropion With DRD2 A1 Allele | 35.281 | 16.385 |
| Placebo w/o DRD2 A1 Allele | 33.672 | 18.017 |
| Placebo With DRD2 A1 Allele | 33.984 | 18.902 |
| Varenicline w/o DRD2 A1 Allele | 35.507 | 15.93 |
| Varenicline With DRD2 A1 Allele | 37.315 | 14.98 |
Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months
| Intervention | score on a scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Anger | Anxiety | Concentration | Craving | Hunger | Sadness | Sleep | |
| Bupropion w/o DRD2 A1 Allele | 4.28 | 6.587 | 4.238 | 6.814 | 9.79 | 4.005 | 9.672 |
| Bupropion With DRD2 A1 Allele | 4.41 | 6.587 | 3.935 | 6.78 | 11.082 | 4.338 | 9.528 |
| Placebo w/o DRD2 A1 Allele | 5.584 | 7.785 | 4.764 | 9.024 | 11.207 | 5.293 | 9.078 |
| Placebo With DRD2 A1 Allele | 5.752 | 7.915 | 4.951 | 8.696 | 11.044 | 5.865 | 8.629 |
| Varenicline w/o DRD2 A1 Allele | 4.394 | 6.218 | 3.743 | 6.646 | 11.016 | 4.246 | 7.721 |
| Varenicline With DRD2 A1 Allele | 4.222 | 5.873 | 3.407 | 6.252 | 10.707 | 3.738 | 8.153 |
The accuracy of self-reported smoking abstinence during study visits was confirmed by an exhaled carbon monoxide (CO) levels and by urinary cotinine levels. 7-day point prevalence abstinence was defined as no cigarettes (not even a puff) in the last 7 days, levels of (CO) in exhaled air < 4 ppm, and concentrations of cotinine in urine < 50 ng/mL. At every visit, a research nurse monitored the smoking status of all subjects (amount of cigarettes per day, exhaled CO). Exhaled CO was measured using a Vitalograph carbon monoxide monitor (Lenexa, KS) according to the manufacturer's recommendations. A urine sample was collected at each visit and cotinine in urine was quantified using the validated liquid chromatography-mass spectrometry (LC/MS) method. We calculated the total number of abstinent subjects. The higher the number the better outcome. (NCT01390246)
Timeframe: Visit 6 (end of 12 weeks of medication therapy)
| Intervention | Participants (Count of Participants) |
|---|---|
| Bupropion SR | 5 |
| Placebo | 1 |
The accuracy of self-reported smoking abstinence during study visits was confirmed by an exhaled carbon monoxide (CO) levels and by urinary cotinine levels. 7-day point prevalence abstinence was defined as no cigarettes (not even a puff) in the last 7 days, levels of (CO) in exhaled air < 4 ppm, and concentrations of cotinine in urine < 50 ng/mL. At every visit, a research nurse monitored the smoking status of all subjects (amount of cigarettes per day, exhaled CO). Exhaled CO was measured using a Vitalograph carbon monoxide monitor (Lenexa, KS) according to the manufacturer's recommendations. A urine sample was collected at each visit and cotinine in urine was quantified using the validated liquid chromatography-mass spectrometry (LC/MS) method. We calculated the total number of abstinent subjects. The higher the number the better outcome. (NCT01390246)
Timeframe: End of pregnancy (visit 7) is a time period between 36.0-38.6 weeks gestation
| Intervention | Participants (Count of Participants) |
|---|---|
| Bupropion SR | 3 |
| Placebo | 1 |
Cigarette craving and withdrawal symptoms were assessed by the Minnesota Nicotine Withdrawal Scale (MNWS). MNWS consists of 7 objectives (e.g., irritability, anxious, depressed mood, difficulty concentrating, increased appetite, insomnia, restless). Subjects were given a score on each item on a scale of 0 (not present) to 4 (severe). Summed (total) score excluding craving represent subject's symptoms of tobacco withdrawal, ranging from 0 to 28. We calculated a craving for tobacco score and a total score of withdrawal symptoms excluding craving. The higher score represent more sever craving and withdrawal. (NCT01390246)
Timeframe: During treatment: Visits 2-6 (time period between 2nd and 12th week of therapy)
| Intervention | MNWS Score (Mean) | |
|---|---|---|
| Craving for tobacco | Total score of withdrawal excluding craving | |
| Bupropion SR | 1.50 | 3.77 |
| Placebo | 2.07 | 5.35 |
Cigarette craving and withdrawal symptoms were assessed by the Minnesota Nicotine Withdrawal Scale (MNWS). MNWS consists of 7 objectives (e.g., irritability, anxious, depressed mood, difficulty concentrating, increased appetite, insomnia, restless). Subjects were given a score on each item on a scale of 0 (not present) to 4 (severe). Summed (total) score excluding craving represent subject's symptoms of tobacco withdrawal, ranging from 0 to 28. We calculated a craving for tobacco score and a total score of withdrawal symptoms excluding craving. The higher score represent more sever craving and withdrawal. (NCT01390246)
Timeframe: Quit date, visit 2 (one week after starting the 12-week course of therapy)
| Intervention | MNWS Score (Mean) | |
|---|---|---|
| Craving for tobacco | Total score of withdrawal excluding craving | |
| Bupropion SR | 2.04 | 4.75 |
| Placebo | 2.33 | 4.88 |
Latency to Relapse during the first 12 months post-quit, with relapse defined as 7 consecutive days of smoking; this outcome will be analyzed in a Cox regression survival analysis model with non-relapsers coded as right-censored (NCT01120704)
Timeframe: Assessed during the first 12 months post-quit after target quit day
| Intervention | participants (Number) | |
|---|---|---|
| # Participants Who Relapsed (Smoking) | # Participants Who Did Not Relapse (Not Smoking) | |
| 26 Weeks of Nicotine Patch and Nicotine Gum | 209 | 66 |
| 8 Weeks of Nicotine Patch and Nicotine Gum | 227 | 42 |
| Automated Adherence Prompting Phone Calls | 218 | 54 |
| Cognitive Medication Adherence Counseling | 222 | 49 |
| Electronic Medication Monitoring Device Plus Feedback | 211 | 59 |
| Electronic Medication Monitoring Device Without Feedback | 225 | 49 |
| Maintenance Counseling | 208 | 55 |
| No Automated Adherence Prompting Phone Calls | 218 | 54 |
| No Cognitive Medication Adherence Counseling | 214 | 59 |
| No Maintenance Counseling | 228 | 53 |
"Self-Reported 7-Day Point-Prevalence Abstinence is a dichotomous outcome with values of 0 and 1 where 0=smoking on one or more of the past 7 days at the assessment endpoint (52 weeks post-quit) and 1=no smoking on any of the past 7 days at the assessment endpoint (i.e., abstinent for the past 7 days); this outcome will be analyzed in a logistic regression analysis model.~Note: This abstinence primary outcome replaces latency to relapse (now designated as a secondary outcome) because reviewers of the now-accepted manuscript (at the journal Addiction) advised us to change the primary outcome to the current week 52 Self-Reported 7-Day Point-Prevalence Abstinence." (NCT01120704)
Timeframe: Assessed at 52 weeks after target quit day
| Intervention | participants (Number) | |
|---|---|---|
| # Participants Who Smoking | # Participants Who Are Abstinent | |
| 26 Weeks of Nicotine Patch and Nicotine Gum | 181 | 94 |
| 8 Weeks of Nicotine Patch and Nicotine Gum | 197 | 72 |
| Automated Adherence Prompting Phone Calls | 180 | 90 |
| Cognitive Medication Adherence Counseling | 194 | 77 |
| Electronic Medication Monitoring Device Plus Feedback | 192 | 80 |
| Electronic Medication Monitoring Device Without Feedback | 186 | 86 |
| Maintenance Counseling | 176 | 87 |
| No Automated Adherence Prompting Phone Calls | 198 | 76 |
| No Cognitive Medication Adherence Counseling | 184 | 89 |
| No Maintenance Counseling | 202 | 79 |
(NCT00136760)
Timeframe: 3 weeks
| Intervention | cigarettes per day (Mean) |
|---|---|
| CM + BUP | 12.7 |
| CM + PLA | 13.9 |
| NR + BUP | 18.8 |
| NR + PLA | 21.0 |
Urinary Cotinine levels at Week 4 (average of last 3 study visits) (NCT00136760)
Timeframe: 3 weeks
| Intervention | ng/ml (Mean) |
|---|---|
| CM + BUP | 755 |
| CM + PLA | 1102 |
| NR + BUP | 1534 |
| NR + PLA | 1408 |
A self-report measure of continuous abstinence at end of treatment. It is defined as the number of consecutive days without smoking a cigarette for each subject, as determined by the Timeline Followback (TLFB), completed by research staff. The TLFB is an assessment tool that obtains estimates of daily smoking. Using a calendar, people provide retrospective estimates of their daily smoking over a specified time period that can vary up to 12 months from the interview date. The TLFB has also been used to assess other forms of substance abuse (e.g., alcohol, drugs, etc.). (NCT00326781)
Timeframe: End of Treatment (8-weeks after quit date)
| Intervention | Participants (Number) |
|---|---|
| Transdermal Nicotine | 83 |
| Nicotine Nasal Spray | 75 |
"End-of-Treatment (EOT) is defined as the phone survey that takes place at the end of each subject's nicotine replacement therapy treatment. The EOT took place up to 8 weeks after participants began the study and also utilized the Timeline Followback. It is a 7-day point prevalence measure describing a subject's ability to remain abstinent from smoking for the 7 previous days occurring before a subject's EOT phone survey.~This was verified by a Carbon Monoxide breath reading taking place within a week of a subject's End of Treatment phone survey." (NCT00326781)
Timeframe: End of Treatment
| Intervention | participants (Number) |
|---|---|
| Transdermal Nicotine | 112 |
| Nicotine Nasal Spray | 95 |
"Number of participants who report Not Smoking (not even a puff) in past 7 days when asked at week 8" (NCT01015170)
Timeframe: End of Treatment (8 weeks after Zyban start date)
| Intervention | participants (Number) | |
|---|---|---|
| Still smoking | Quit smoking | |
| Nicotine Replacement & Behavioural Support | 109 | 106 |
30 reviews available for bupropion and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Understanding Stimulant Use and Use Disorders in a New Era.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adult; Anticonvulsants; Behavior Therapy; Bupropion; Centra | 2022 |
Smoking reduction interventions for smoking cessation.
Topics: Bupropion; Humans; Nicotine; Nicotinic Agonists; Randomized Controlled Trials as Topic; Smoking Cess | 2019 |
Impact of Smoking and Smoking Cessation Medications in Aviators.
Topics: Bupropion; Electronic Nicotine Delivery Systems; Humans; Military Personnel; Nicotinic Agonists; Pil | 2019 |
Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions.
Topics: Analgesics, Opioid; Bupropion; Forecasting; Humans; Methadone; Opioid-Related Disorders; Randomized | 2015 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azepines; Azocines; Benzazepines; Bupropion; Counseling; Heterocyclic Compounds, 4 or Mor | 2016 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug T | 2016 |
A preliminary benefit-risk assessment of varenicline in smoking cessation.
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agoni | 2009 |
Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.
Topics: Animals; Benzazepines; Bupropion; Clinical Trials as Topic; Humans; Nicotine; Quinoxalines; Receptor | 2009 |
Smoking cessation-recent advances.
Topics: Australia; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Therap | 2010 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Qu | 2010 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Qu | 2011 |
Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.
Topics: Adolescent; Benzazepines; Bupropion; Clinical Trials as Topic; Dopamine Uptake Inhibitors; Humans; N | 2012 |
Comparative dynamics of four smoking withdrawal symptom scales.
Topics: Administration, Inhalation; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Huma | 2012 |
Comparative dynamics of four smoking withdrawal symptom scales.
Topics: Administration, Inhalation; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Huma | 2012 |
Comparative dynamics of four smoking withdrawal symptom scales.
Topics: Administration, Inhalation; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Huma | 2012 |
Comparative dynamics of four smoking withdrawal symptom scales.
Topics: Administration, Inhalation; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Huma | 2012 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azepines; Azocines; Benzazepines; Bupropion; Counseling; Heterocyclic Compounds, 4 or Mor | 2012 |
[Smoking in COPD].
Topics: Benzazepines; Bupropion; Clonidine; Comorbidity; Disease Progression; Europe; Humans; Motivation; Ni | 2011 |
Clinical efficacy of bupropion in the management of smoking cessation.
Topics: Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Drug Administration | 2002 |
Current approaches to the management of smoking cessation.
Topics: Bupropion; Delayed-Action Preparations; Hotlines; Humans; Nicotine; Practice Guidelines as Topic; Ps | 2002 |
Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy?
Topics: Bupropion; Clinical Trials as Topic; Drug Administration Schedule; Humans; Nicotine; Nicotinic Agoni | 2002 |
Effects of smoked marijuana in healthy and HIV + marijuana smokers.
Topics: Bupropion; Dronabinol; Eating; HIV Seropositivity; Humans; Marijuana Smoking; Piperazines; Substance | 2002 |
Does bupropion have advantages over other medical therapies in the cessation of smoking?
Topics: Administration, Cutaneous; Aged; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; | 2004 |
Smoking cessation in patients with coronary artery disease.
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Oral; Atherosclerosis; Behavi | 2005 |
How does bupropion work as a smoking cessation aid?
Topics: Administration, Cutaneous; Bupropion; Dopamine; Dopamine Uptake Inhibitors; Double-Blind Method; Hum | 2005 |
Medication screening for smoking cessation: a proposal for new methodologies.
Topics: Administration, Cutaneous; Administration, Oral; Antidepressive Agents, Second-Generation; Bupropion | 2006 |
Bupropion for the treatment of nicotine withdrawal and craving.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Dose-Response Relatio | 2006 |
Bupropion for the treatment of nicotine withdrawal and craving.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Dose-Response Relatio | 2006 |
Bupropion for the treatment of nicotine withdrawal and craving.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Dose-Response Relatio | 2006 |
Bupropion for the treatment of nicotine withdrawal and craving.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Dose-Response Relatio | 2006 |
Management of methamphetamine abuse and dependence.
Topics: Baclofen; Benzhydryl Compounds; Brain; Bupropion; Cognition Disorders; Cognitive Behavioral Therapy; | 2006 |
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.
Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidi | 2007 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delay | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delay | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delay | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delay | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delay | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delay | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delay | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delay | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delay | 2008 |
Treating anxiety in patients with alcoholism.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Alcoholism; Antidepressive Agents; Anxiety Disorders | 1995 |
[Therapeutic advances in breaking the tobacco habit].
Topics: Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; | 1999 |
Bupropion sustained release. A therapeutic review of Zyban.
Topics: Antidepressive Agents, Second-Generation; Australia; Bupropion; Contraindications; Counseling; Delay | 2002 |
43 trials available for bupropion and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Anhedonia: Its Dynamic Relations With Craving, Negative Affect, and Treatment During a Quit Smoking Attempt.
Topics: Adult; Anhedonia; Bupropion; Craving; Female; Humans; Male; Nicotine; Smoking Cessation; Substance W | 2017 |
Self-initiated gradual smoking reduction among community correction smokers.
Topics: Adult; Age of Onset; Black or African American; Bupropion; Cigar Smoking; Cigarette Smoking; Counsel | 2019 |
Smoking abstinence symptoms across 67 days compared with randomized controls-Moderation by nicotine replacement therapy, bupropion, and negative-affect traits.
Topics: Administration, Cutaneous; Adult; Anxiety; Behavior Therapy; Bupropion; Cigarette Smoking; Craving; | 2019 |
A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Analgesics, Opioid; Behavior, Addictive; Buprenorp | 2019 |
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Combined Modality Therapy; Counseling; Del | 2013 |
Effects of bupropion on cognitive performance during initial tobacco abstinence.
Topics: Adult; Antidepressive Agents, Second-Generation; Attention; Bupropion; Cognition Disorders; Cross-Ov | 2013 |
A test of the stress-buffering model of social support in smoking cessation: is the relationship between social support and time to relapse mediated by reduced withdrawal symptoms?
Topics: Adolescent; Adult; Aged; Bupropion; Chronic Disease; Cognitive Behavioral Therapy; Counseling; Depre | 2015 |
Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Drug Therapy, Combi | 2016 |
Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Breath Tests; Bupropion; Carbon Dioxide; Cotinine; | 2017 |
Psychological mediators of bupropion sustained-release treatment for smoking cessation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Behavior, Addictive; Bupropion; Delayed-Action Preparati | 2008 |
Extended cognitive behavior therapy for cigarette smoking cessation.
Topics: Adult; Bupropion; Carbon Monoxide; Cognitive Behavioral Therapy; Counseling; Dopamine Uptake Inhibit | 2008 |
Extended cognitive behavior therapy for cigarette smoking cessation.
Topics: Adult; Bupropion; Carbon Monoxide; Cognitive Behavioral Therapy; Counseling; Dopamine Uptake Inhibit | 2008 |
Extended cognitive behavior therapy for cigarette smoking cessation.
Topics: Adult; Bupropion; Carbon Monoxide; Cognitive Behavioral Therapy; Counseling; Dopamine Uptake Inhibit | 2008 |
Extended cognitive behavior therapy for cigarette smoking cessation.
Topics: Adult; Bupropion; Carbon Monoxide; Cognitive Behavioral Therapy; Counseling; Dopamine Uptake Inhibit | 2008 |
Randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking cessation.
Topics: Bupropion; Community Pharmacy Services; Cotinine; Female; Humans; Male; Medication Adherence; Middle | 2009 |
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Femal | 2010 |
Do smokers know what we're talking about? The construct validity of nicotine dependence questionnaire measures.
Topics: Administration, Oral; Adult; Bupropion; Chewing Gum; Combined Modality Therapy; Counseling; Depressi | 2009 |
A bupropion smoking cessation clinical trial for cancer patients.
Topics: Administration, Cutaneous; Antidepressive Agents, Second-Generation; Bupropion; Depression; Depressi | 2010 |
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Topics: Adolescent; Adult; Aged; Benzazepines; Breath Tests; Bupropion; Carbon Monoxide; Delayed-Action Prep | 2010 |
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Topics: Adolescent; Adult; Aged; Benzazepines; Breath Tests; Bupropion; Carbon Monoxide; Delayed-Action Prep | 2010 |
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Topics: Adolescent; Adult; Aged; Benzazepines; Breath Tests; Bupropion; Carbon Monoxide; Delayed-Action Prep | 2010 |
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
Topics: Adolescent; Adult; Aged; Benzazepines; Breath Tests; Bupropion; Carbon Monoxide; Delayed-Action Prep | 2010 |
Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment.
Topics: Adolescent; Anxiety Disorders; Bupropion; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Comb | 2011 |
Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Bupropion; Counseling; Fe | 2011 |
Tobacco withdrawal components and their relations with cessation success.
Topics: Adult; Affect; Bupropion; Double-Blind Method; Humans; Multivariate Analysis; Nicotine; Nicotinic Ag | 2011 |
Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia.
Topics: Adult; Behavior Therapy; Behavior, Addictive; Breath Tests; Bupropion; Carbon Monoxide; Combined Mod | 2011 |
The dynamics of the urge-to-smoke following smoking cessation via pharmacotherapy.
Topics: Administration, Intranasal; Black People; Body Mass Index; Bupropion; Dopamine Uptake Inhibitors; Fe | 2011 |
Why two smoking cessation agents work better than one: role of craving suppression.
Topics: Adult; Affect; Bayes Theorem; Bupropion; Combined Modality Therapy; Counseling; Drug Therapy, Combin | 2012 |
A comparison of three smokeless tobacco dependence measures.
Topics: Adult; Aged; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Humans; Male; Middle Aged; | 2012 |
Perceived treatment assignment and smoking cessation in a clinical trial of bupropion versus placebo.
Topics: Bupropion; Female; Humans; Male; Middle Aged; Placebos; Smoking Cessation; Substance Withdrawal Synd | 2013 |
Possible reinforcement enhancing effects of bupropion during initial smoking abstinence.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cross-Over Studies; Double-Blind Method; | 2013 |
Smoking withdrawal dynamics: II. Improved tests of withdrawal-relapse relations.
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans | 2003 |
A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation.
Topics: Adult; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Fema | 2003 |
Smoking withdrawal dynamics: III. Correlates of withdrawal heterogeneity.
Topics: Administration, Cutaneous; Bupropion; Chi-Square Distribution; Dopamine Uptake Inhibitors; Double-Bl | 2003 |
Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Ganglionic Stimulants; Ge | 2003 |
Effect of glucose on tobacco withdrawal symptoms in recent quitters using bupropion or nicotine replacement.
Topics: Adult; Bupropion; Double-Blind Method; Female; Glucose; Humans; Male; Nicotine; Smoking Cessation; S | 2004 |
Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 2005 |
Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
Topics: Administration, Intranasal; Adult; Alleles; Antidepressive Agents, Second-Generation; Bupropion; Dou | 2006 |
Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
Topics: Administration, Intranasal; Adult; Alleles; Antidepressive Agents, Second-Generation; Bupropion; Dou | 2006 |
Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
Topics: Administration, Intranasal; Adult; Alleles; Antidepressive Agents, Second-Generation; Bupropion; Dou | 2006 |
Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
Topics: Administration, Intranasal; Adult; Alleles; Antidepressive Agents, Second-Generation; Bupropion; Dou | 2006 |
Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h.
Topics: Adult; Antidepressive Agents, Second-Generation; Appetite; Bupropion; Circadian Rhythm; Cross-Over S | 2005 |
Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia.
Topics: Adult; Attention; Bupropion; Cognition Disorders; Delayed-Action Preparations; Dopamine Uptake Inhib | 2005 |
A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation.
Topics: Adolescent; Adult; Amines; Bupropion; Cyclohexanecarboxylic Acids; Dopamine Uptake Inhibitors; Excit | 2005 |
A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results.
Topics: Adrenergic Uptake Inhibitors; Bupropion; Counseling; Delayed-Action Preparations; Double-Blind Metho | 2006 |
Subjective reactivity to the first cigarette of the day as a predictor of smoking relapse: a preliminary study.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Behavior Therapy; Bupropi | 2007 |
A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind | 2008 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A comparison of sustained-release bupropion and placebo for smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; | 1997 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Actio | 1999 |
The effect of bupropion on nicotine craving and withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Female; Humans; Mal | 2000 |
The effect of bupropion on nicotine craving and withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Female; Humans; Mal | 2000 |
The effect of bupropion on nicotine craving and withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Female; Humans; Mal | 2000 |
The effect of bupropion on nicotine craving and withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Female; Humans; Mal | 2000 |
The effect of bupropion on nicotine craving and withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Female; Humans; Mal | 2000 |
The effect of bupropion on nicotine craving and withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Female; Humans; Mal | 2000 |
The effect of bupropion on nicotine craving and withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Female; Humans; Mal | 2000 |
The effect of bupropion on nicotine craving and withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Female; Humans; Mal | 2000 |
The effect of bupropion on nicotine craving and withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Double-Blind Method; Female; Humans; Mal | 2000 |
Bupropion SR worsens mood during marijuana withdrawal in humans.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Bupropion; Cannabis; Eating; Female; Humans | 2001 |
Acute doses of d-amphetamine and bupropion increase cigarette smoking.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Bupropion; Central Nervous System Stimulant | 2001 |
42 other studies available for bupropion and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Bupropion/zonisamide combination to assist smokers to switch from combustible cigarettes to electronic nicotine delivery systems (ENDS).
Topics: Adult; Bupropion; Electronic Nicotine Delivery Systems; Humans; Nicotine; Smokers; Substance Withdra | 2022 |
Abstinence Rate, Adverse Events and Withdrawal Symptoms after Varenicline Use and Predicting Factors of Smoking Abstinence: A Multicentre Single-State Study in Malaysia.
Topics: Adolescent; Adult; Benzazepines; Bupropion; Cohort Studies; Humans; Malaysia; Nicotinic Agonists; Qu | 2022 |
Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study.
Topics: Accidental Falls; Accidents, Traffic; Adult; Bupropion; Cardiovascular Diseases; Cross-Over Studies; | 2018 |
Evaluating the effect of smoking cessation treatment on a complex dynamical system.
Topics: Bupropion; Craving; Drug Therapy, Combination; Fatigue; Humans; Nicotine; Smoking Cessation; Substan | 2017 |
[Reversible cerebral vasoconstriction syndrome following smoking cessation and treatment with bupropion].
Topics: Apraxias; Bupropion; Calcium Channel Blockers; Carotid Stenosis; Cerebral Arteries; Cerebrovascular | 2018 |
Bupropion attenuates morphine tolerance and dependence: Possible role of glutamate, norepinephrine, inflammation, and oxidative stress.
Topics: Animals; Brain; Bupropion; Dose-Response Relationship, Drug; Drug Tolerance; Glutamic Acid; Glutathi | 2018 |
Beliefs and reality of e-cigarette smoking.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Chills; Depressive Disorder; Electronic | 2018 |
Predictors of success for smoking cessation at the workplace: a longitudinal study.
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Bupropion; Counseling; Dyspnea; Educational Status; | 2014 |
Varenicline may reduce negative effect while aiding smoking cessation.
Topics: Benzazepines; Bupropion; Counseling; Depression; Female; Humans; Male; Nicotinic Agonists; Quinoxali | 2014 |
A case of hypomania during nicotine cessation treatment with bupropion.
Topics: Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Dysthymic Disorder; Hum | 2013 |
Searching for phenotypes in smoking cessation treatment.
Topics: Adult; Aged; Behavior Therapy; Benzazepines; Bupropion; Effect Modifier, Epidemiologic; Female; Huma | 2014 |
Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Bupropion; Conditioning, Psychological; Dr | 2008 |
Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion.
Topics: Animals; Bupropion; Depression; Dose-Response Relationship, Drug; Drug Administration Routes; Gene E | 2008 |
Gender differences among smokers receiving interventions for tobacco dependence in a medical setting.
Topics: Analysis of Variance; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Male; Mid | 2009 |
[Preventing weight gain in smoking cessation: there is no miracle solution].
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Fluoxetine; Humans; | 2009 |
Bupropion-associated premature ejaculation.
Topics: 4-Butyrolactone; Adolescent; Bupropion; Dopamine Uptake Inhibitors; Ejaculation; Humans; Male; Solve | 2010 |
Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice.
Topics: Animals; Anxiety; Behavior, Animal; Bupropion; Conditioning, Operant; Discrimination Learning; Discr | 2010 |
[Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care].
Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Longitudinal | 2011 |
Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking".
Topics: Benzazepines; Bupropion; Chewing Gum; Counseling; Delayed-Action Preparations; Drug Administration S | 2011 |
Alpha oscillations in response to affective and cigarette-related stimuli in smokers.
Topics: Adult; Attention; Benzazepines; Brain; Bupropion; Cues; Demography; Electroencephalography Phase Syn | 2013 |
Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzazepines; Brazil; Bupropion; Demography; Drug T | 2013 |
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Bupropion; Drug Administration Schedule; E | 2003 |
Bupropion-induced somnambulism.
Topics: Adult; Amnesia; Bupropion; Dopamine Uptake Inhibitors; Humans; Male; Nicotine; Smoking Cessation; So | 2003 |
Stopping smoking can cause constipation.
Topics: Bupropion; Constipation; Dopamine Uptake Inhibitors; Female; Humans; Male; Middle Aged; Nicotine; Ps | 2003 |
A case report of mania related to discontinuation of bupropion therapy for smoking cessation.
Topics: Acute Disease; Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Delusions; Female; Humans; | 2004 |
[Recommendation of good practice: Therapeutic strategies, with or without the assistance of medicine-based treatment, for stopping smoking (May 2003)].
Topics: Adolescent; Alcohol Drinking; Bupropion; Cotinine; Female; Humans; MEDLINE; Nicotine; Pregnancy; Smo | 2004 |
Is antagonism of alpha3beta4 nicotinic receptors a strategy to reduce morphine dependence?
Topics: Acute Disease; Animals; Bupropion; Dextromethorphan; Drug Therapy, Combination; Female; Mecamylamine | 2005 |
Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat.
Topics: Animals; Body Weight; Bupropion; Chromatography, High Pressure Liquid; Dopamine; Dopamine Plasma Mem | 2005 |
Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice.
Topics: Animals; Anxiety; Bupropion; Dopamine; Drug Tolerance; Female; Male; Mice; Motor Activity; Norepinep | 2005 |
Bupropion attenuates nicotine abstinence syndrome in the rat.
Topics: Animals; Association Learning; Avoidance Learning; Bupropion; Conditioning, Classical; Dopamine Upta | 2006 |
Variation in bupropion findings is not due to differences in measurement: comment on Teneggi et al.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Delayed-Action Preparation | 2006 |
Effect of bupropion on physiological measures of stress in smokers during nicotine withdrawal.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Pressure; Bupropion; Counseling; Epinephrine; | 2006 |
Acute dystonia resulting from abrupt bupropion discontinuation.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Dystonia; Humans; M | 2007 |
Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell.
Topics: Animals; Bupropion; Dopamine; Dopamine Uptake Inhibitors; Drug Administration Schedule; Male; Nucleu | 2007 |
Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal.
Topics: Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Dose-Response Relationship, Drug; | 2007 |
Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning.
Topics: Animals; Bupropion; Conditioning, Psychological; Dopamine; Dose-Response Relationship, Drug; Fear; M | 2007 |
The search for medications to treat stimulant dependence.
Topics: Amphetamine-Related Disorders; Benzhydryl Compounds; Brain; Bupropion; Cocaine; Cocaine-Related Diso | 2008 |
Treating tobacco addiction--nicotine or no nicotine?
Topics: Antidepressive Agents; Bupropion; Humans; Nicotine; Nortriptyline; Smoking Cessation; Substance With | 1997 |
Zyban: a new aid to smoking cessation treatment--will it work for psychiatric patients?
Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Interactions; Drug Therapy, Combination; H | 1999 |
Bupropion for amphetamine withdrawal syndrome.
Topics: Adolescent; Amphetamine; Antidepressive Agents, Second-Generation; Bupropion; Humans; Male; Substanc | 2001 |
[Bupropion. An antidepressant used to help smoking cessation].
Topics: Antidepressive Agents, Second-Generation; Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; P | 2002 |
Substitution of psychoactive drugs in pentobarbital-dependent rats.
Topics: Animals; Antidepressive Agents; Arousal; Body Weight; Brain; Bromazepam; Bupropion; Diazepam; Dose-R | 1990 |